Thursday - April 25, 2024
OPKO, Pfizer Announce Positive Phase 3 Results for Somatrogon
October 21, 2019
MIAMI, Florida, Oct. 21 -- Pfizer, a pharmaceutical company, issued the following news release:

* * *

- An Investigational Long-Acting Human Growth Hormone to Treat Children With Growth Hormone Deficiency

* * *

MIAMI and NEW YORK - OPKO Health Inc. (NASDAQ: OPK) and Pfizer Inc. (NYSE: PFE) announced today that the global Phase 3 trial evaluating somatrogon dosed once-weekly in pre-pubertal children with growth hormone deficiency (GHD) met its p . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your
Affiliation		 Government Newspaper / Media Business
Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products